Evobrutinib treatment improves neurological function of mice with cerebral ischemia, and alleviates neuroinflammation by inhibiting M1 microglia polarization through TLR4/Myd88/NF-κB pathway. The gene discussed is NFKB1; the disease is Cerebral ischemia.